Denzerini
Nov 17, 9:23 PM
$HYPR The patient, and opportunistic, will be rewarded. The company continues to execute well with the proof being their continued sales growth, and consistent meeting and beating quarterly estimates. The margins will be expanding also once they receive FDA approval for contrast. The TAM is quite large — especially when including international. Then there are the 197 issued patents plus 160 pending.
I understand that it is a major bummer to watch the stock sink every day, but this has been happening with most MedTech micro cap companies lately. Then there are the Russell 3000 funds that have to sell HYPR in the short term.
As it always has done historically, the stock of a business that continues to beat/exceed its estimated sales growth, and at least maintains its margins, will eventually experience a sustainable long-term rise. This painful period should be viewed as a special opportunity to purchase stock at a discount while it’s floating under the radar.
1 replies